These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 32906729)

  • 21. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
    Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
    Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer.
    Silva VL; Saxena J; Nicolini F; Hoare JI; Metcalf S; Martin SA; Lockley M
    Cell Death Dis; 2021 Apr; 12(4):395. PubMed ID: 33854036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
    Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
    Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.
    Guo Q; Lu L; Liao Y; Wang X; Zhang Y; Liu Y; Huang S; Sun H; Li Z; Zhao L
    Cell Death Dis; 2018 Jan; 8(1):e3178. PubMed ID: 29324735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells.
    Han X; Chen H; Zhou J; Steed H; Postovit LM; Fu Y
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30049957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
    Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
    Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
    Ricci F; Guffanti F; Damia G; Broggini M
    Mol Cancer; 2017 May; 16(1):97. PubMed ID: 28558767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COM33 suppresses carboplatin-induced epithelial-mesenchymal transition via inhibition of Twist1 in ovarian cancer.
    Zhou Z; Jin L; Shen J; Shi W; Xu Y; Ye L; Liu J; Pan J
    Acta Biochim Biophys Sin (Shanghai); 2022 Dec; 55(1):34-42. PubMed ID: 36647720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adipocyte pyroptosis occurs in omental tumor microenvironment and is associated with chemoresistance of ovarian cancer.
    Lin CN; Liang YL; Tsai HF; Wu PY; Huang LY; Lin YH; Kang CY; Yao CL; Shen MR; Hsu KF
    J Biomed Sci; 2024 Jun; 31(1):62. PubMed ID: 38862973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of estrogen receptor α by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells.
    Matsumura S; Ohta T; Yamanouchi K; Liu Z; Sudo T; Kojimahara T; Seino M; Narumi M; Tsutsumi S; Takahashi T; Takahashi K; Kurachi H; Nagase S
    Cancer Biol Ther; 2017 Sep; 18(9):730-739. PubMed ID: 27689466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
    Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
    Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance.
    Somasagara RR; Spencer SM; Tripathi K; Clark DW; Mani C; Madeira da Silva L; Scalici J; Kothayer H; Westwell AD; Rocconi RP; Palle K
    Oncogene; 2017 Nov; 36(48):6680-6690. PubMed ID: 28806395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells.
    Carmi YK; Agbarya A; Khamaisi H; Farah R; Shechtman Y; Korobochka R; Gopas J; Mahajna J
    Transl Oncol; 2024 Jun; 44():101939. PubMed ID: 38489872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.
    Li L; Luan Y; Wang G; Tang B; Li D; Zhang W; Li X; Zhao J; Ding H; Reed E; Li QQ
    Int J Mol Med; 2004 Aug; 14(2):257-64. PubMed ID: 15254775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.
    Havasi A; Cainap SS; Havasi AT; Cainap C
    Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Notch3 induces epithelial-mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells.
    Gupta N; Xu Z; El-Sehemy A; Steed H; Fu Y
    Gynecol Oncol; 2013 Jul; 130(1):200-6. PubMed ID: 23542683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.
    Ryner L; Guan Y; Firestein R; Xiao Y; Choi Y; Rabe C; Lu S; Fuentes E; Huw LY; Lackner MR; Fu L; Amler LC; Bais C; Wang Y
    Clin Cancer Res; 2015 Jul; 21(13):2941-51. PubMed ID: 25838397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
    Monk BJ; Coleman RL
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S63-7. PubMed ID: 19955917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro.
    Zhu Z; Mu Y; Qi C; Wang J; Xi G; Guo J; Mi R; Zhao F
    Int J Mol Med; 2015 Feb; 35(2):340-8. PubMed ID: 25516145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.